AKT1 and melanoma: Taking all results together, the NECTIN4 induction and the subsequent PI3K/Akt pathway activation may cause BRAFi resistance and promote melanoma cell proliferation, suggesting that NECTIN4-targeted therapy may serve as a potent treatment for patients with BRAFi-resistant melanoma.